NCT02007941View on ClinicalTrials.gov

Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Renal ImpairmentHealthy
Interventions
DRUG

CKD-501

From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .

Trial Locations (1)

Unknown

The Inje University Busan Paik Hospital, Busan

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY